TLIS Stock Ownership Activity

TALIS BIOMEDICAL CORP 13F holders

No value investing guru has made any change to the TALIS BIOMEDICAL CORP (TLIS) position according to the gurus' latest SEC quarterly report(s).

Which gurus or hedge funds are buying TLIS now?

According to the latest SEC filing(s) TALIS BIOMEDICAL CORP (TLIS) has not been purchased by any super investor.

To see more about who is investing in TALIS BIOMEDICAL CORP (TLIS), please go to the TLIS ownership page.

2023 Q3 (1 result)
David Einhorn
-100.00%
-149,052
-0.06%
0.00%
Current price: $1.69 76.53% Reported price*: $7.20
2022 Q1 (1 result)
David Einhorn
+42.47%
+44,432
+0.06%
0.20%
Current price: $1.69 92.01% Reported price*: $21.15
2021 Q4 (1 result)
David Einhorn
buy
+104,620
+0.38%
0.38%
Current price: $1.69 97.19% Reported price*: $60.15
3 of 3

Shares, change to shares, sold shares - split-adjusted.

Reported price - this doesn't represent the actual buy or sell price.
It is the split-adjusted price of the security as of the last day of the reported period.

Value or Price - If the security is completely sold out, we show the reported value (or price) prior to the actual period.